Table 1 Targeted agents in development for HCC
From: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
Agent | Anti-angiogenic targets | Anti-proliferative targets | Clinical Development | ||||
|---|---|---|---|---|---|---|---|
| Â | VEGF | VEGFR | PDGFR | EGFR | Raf | mTOR | Â |
Bevacizumab | • |  |  |  |  |  | Phase II ongoing |
Brivanib |  | • |  |  |  |  | Phase II recruiting |
Cediranib |  | • |  |  |  |  | Phase II recruiting |
Erlotinib |  |  |  | • |  |  | Phase II complete |
Gefitinib |  |  |  | • |  |  | Phase II complete |
Cetuximab |  |  |  | • |  |  | Phase II complete |
Lapatinib |  |  |  | • |  |  | Phase II ongoing |
RAD001 |  |  |  |  |  | • | Phase I/II recruiting |
Sorafenib* |  | • | • |  | • |  | Phase III complete |
Sunitinib* |  | • | • |  |  |  | Phase II ongoing |
Thalidomide | • |  |  |  |  |  | Phase III recruiting |